Comparative Pharmacology
Head-to-head clinical analysis: ALCAINE versus LARYNGOTRACHEAL ANESTHESIA KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAINE versus LARYNGOTRACHEAL ANESTHESIA KIT.
ALCAINE vs LARYNGOTRACHEAL ANESTHESIA KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
None Documented
None Documented
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
Renal excretion of parent drug and metabolites: <5% unchanged.
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Category C
Category C
Local Anesthetic
Local Anesthetic